|
Patients
with primary sclerosing cholangitis and inflammatory bowel disease
who undergo liver transplants have an increased risk of developing
colorectal cancer, according to British researchers.
About 70 percent
of the patients with primary sclerosing cholangitis, a bile duct
disease that often leads to cirrhosis of the liver, also have
an inflammatory bowel disease, especially ulcerative colitis in
which the colon becomes inflamed and ulcerated.
Researchers
at Queen Elizabeth Hospital in Birmingham, in a study of 152 patients
with primary sclerosing cholangitis who underwent 173 liver transplants
between 1986 and 2000, found that the incidence of colorectal
cancer after the transplant was 5.3 percent compared with 0.6
percent in those without the disease.
"All
colorectal cancers in the primary sclerosing cholangitis group
were in [transplant] patients with inflammatory bowel disease
and an intact colon," the researchers reported in the journal
Transplantation.
"The
cumulative risk of developing colorectal cancer in the 83 [transplant]
patients with an intact colon andinflammatory bowel diseas was
14 percent after 5 years and 17 percent after 10 years,"
they said.
They added
that "the cause of death in [the transplant] patients with
colorectal cancer was cancer related in 75 percent of cases."
"Patients
with primary sclerosing cholangitis undergoing liver transplants
with a long history of ulcerative colitis and pancolitis have
an increased risk of developing colorectal cancer with reduced
survival," the researchers concluded. "We advocate long-term
aggressive colonic surveillance and colectomy in selected high-risk
patients with longstanding severe colitis."
Other
Sources: Transplantation
|